Stress Urinary Incontinence (SUI)NCT07186985
The Effectiveness of Combined Pelvic Floor Muscle Training and Vaginal Oestrogen Therapy in Postmenopausal Women With Stress Urinary Incontinence
A study testing Combined Pelvic Floor Muscle Training and Vaginal Oestrogen Therapy and Vaginal estrogen in people with Stress Urinary Incontinence (SUI) and Postmenopausal Women, run by Hanoi Medical University.
Trial summary
The objective of this clinical trial is to investigate whether the combination of pelvic floor muscle training (PFMT) and topical estrogen is more effective in treating stress urinary incontinence (SUI) in postmenopausal women compared to topical estrogen alone. Read more about this study
- Who is it for?
- Any age, women only
- Conditions the study is for
- Stress Urinary Incontinence (SUI), Postmenopausal Women
- What is being tested?
- Combined Pelvic Floor Muscle Training and Vaginal Oestrogen Therapy and Vaginal estrogen
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 115 participants
- Where
- No sites listed yet
- Study dates
- 1 Nov 2025to 28 Feb 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Women only
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Patients diagnosed with stress urinary incontinence.
- Women who have been naturally postmenopausal for at least 1 year or are postmenopausal due to bilateral oophorectomy (surgical removal of both ovaries).
- Have had sexual intercourse to ensure feasibility of urogenital tract examination and assessment.
- Patients who consent to participate in the study and comply with the treatment protocol, including performing pelvic floor muscle training (PFMT) and completing topical vaginal estrogen therapy.
Who cannot join
- Patients with concomitant neurological disorders, urinary tract infections, prior pelvic radiotherapy, or congenital malformations of the lower urinary tract.
- Genitourinary malformations or fistulas causing continuous urinary incontinence.
- Genitourinary cancers or tumors of the urinary tract.
- History of spinal cord injury or central nervous system injury affecting the centers that control urination.
- Patients previously treated for stress urinary incontinence (SUI) (surgery, medications, exercises).
- Patients with severe heart disease, coronary artery disease, or myocardial ischemia.
Show all 14Show fewer
- Patients with pelvic organ prolapse stage III or higher, unexplained vaginal bleeding, confirmed or suspected breast cancer, or vaginitis.
- Presence of premalignant factors or suspected steroid-dependent cancers such as endometrial carcinoma.
- History of or current hepatic tumors, or progressive liver or biliary disease.
- Coagulation/thrombotic disorders, or a history of thromboembolism or stroke.
- Severe hypertriglyceridemia.
- Hypersensitivity to any component of vaginally administered estrogen products.
- The patient or family members are unable to use a smartphone (Android or iOS) to participate in the monitoring program.
- The patient does not agree to participate in the study.
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
The objective of this clinical trial is to investigate whether the combination of pelvic floor muscle training (PFMT) and topical estrogen is more effective in treating stress urinary incontinence (SUI) in postmenopausal women compared to topical estrogen alone. The trial will also analyze factors related to the outcomes of the combined therapy. The key questions this trial aims to answer are:
- Does the combination of PFMT and topical estrogen improve symptoms of stress urinary incontinence in postmenopausal women better than topical estrogen alone?
- Which factors are associated with the effectiveness of the combined therapy?
Read more
Researchers will compare the group receiving the combined therapy (pelvic floor muscle training plus topical estrogen) with the group receiving topical estrogen alone to determine whether adding PFMT to estrogen therapy provides additional treatment benefits for SUI in postmenopausal women.
Participants will:
- Be randomly assigned to one of two groups:
Group 1: Undergo a pelvic floor muscle training (PFMT) program combined with topical estrogen therapy (e.g., vaginal cream/application,...).
Group 2: Receive topical estrogen therapy alone (e.g., vaginal cream/application,...).
- Follow the assigned intervention protocol for a specified duration.
- Attend regular clinic visits for clinical examinations, assessment of incontinence severity, and related measurements.
- Monitor and record their incontinence symptoms and the frequency of urine leakage during daily activities.
- Being tested
- Combined Pelvic Floor Muscle Training and Vaginal Oestrogen Therapy, Vaginal estrogen
- Keywords
- stress urinary incontinence (SUI), postmenopausal women, Pelvic Floor Muscle Training, Vaginal Oestrogen, Pelvic floor rehabilitation
- Medical subject headings
- Urinary Incontinence, Stress
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Combined Pelvic Floor Muscle Training and Vaginal Oestrogen TherapyCombination product
Group 1:
- Patients were instructed to identify and sense their pelvic floor muscles and to perform contraction-hold-relaxation exercises.
- Exercises were performed at a frequency of 8 sets per session, 3 sessions per week, progressing from the supine position (month 1), to sitting (month 2), and to standing (month 3). Training was monitored by an electronic diary app. (Appendix)
- Six individual 45-minute intervention sessions at the center using biofeedback, under the supervision of a physical therapy technician. (Appendix)
- The training program consisted of two parts: resistance training and pre-contraction training (the Knack technique). (Appendix)
- Patients were prescribed and instructed to use 0.5 mg vaginal estrogen for 6 months according to the following regimen:
- First 4 weeks: insert one 0.5 mg tablet nightly at bedtime.
- Next 20 weeks: insert one 0.5 mg tablet at bedtime twice weekly, with 2-3 days between doses
Vaginal estrogenDrug
Patients were prescribed and instructed to use 0.5 mg vaginal estrogen for 6 months according to the following regimen:
First 4 weeks: insert one 0.5 mg tablet nightly at bedtime. Next 20 weeks: insert one 0.5 mg tablet at bedtime twice weekly, with 2-3 days between doses.
| Study group | Role | What they receive |
|---|---|---|
| combination of PFMT and vaginal estrogen. | Experimental | Patients were treated with a combination of a pelvic floor rehabilitation program and 0.5 mg vaginal estrogen. Receives: Combination Product: Combined Pelvic Floor Muscle Training and Vaginal Oestrogen Therapy |
| vaginal estrogen | Active comparator | Patients were treated with 0.5 mg topical vaginal estrogen Receives: Drug: Vaginal estrogen |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes from baseline at 3 and 6 months in One-hour Pad test
One-hour pad test: A noninvasive method that measures the amount of urine leakage collected in an absorbent pad. Standardized by the International Continence Society (ICS), it quantifies leakage during everyday activities, measured in grams (g)
Measured: At baseline, 3 months, and 6 months
Secondary outcomes (6)
Changes from baseline at 3 and 6 months in Patient Global Impression of Improvement (PGI-I scale)
Patient Global Impression of Improvement (PGI-I): Assesses the degree of improvement in urinary incontinence after treatment based on the patient's perception. The scale ranges from "very much better" to "very much worse"
Measured: At baseline, 3 months, and 6 months
Changes from baseline at 3 and 6 months in International Consultation on Incontinence Questionnaire-Urinary Incontinence-Short Form (ICIQ-UI-SF scale)
International Consultation on Incontinence Questionnaire-Urinary Incontinence-Short Form (ICIQ-UI-SF scale): Assesses the severity of urinary incontinence and its impact on quality of life, with scores from 0 to 21. Higher scores indicate more severe incontinence
Measured: At baseline, 3 months, and 6 months
Changes from baseline at 3 and 6 months in Oxford Scale
Oxford Scale: Assesses pelvic floor muscle strength, ranging from 0 (no contraction) to 5 (strong contraction)
Measured: At baseline, 3 months, and 6 months
Changes from baseline at 3 and 6 months in Pelvic floor ultrasound assessment
Bladder neck displacement during pelvic floor muscle contraction on ultrasound: Measurement of bladder neck displacement during pelvic floor muscle contraction, in millimeters (mm)
Measured: At baseline, 3 months, and 6 months
Changes from baseline at 3 and 6 months in Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol scale)
Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol scale): Assesses with a total score from 19 to 76 (higher scores reflect worse quality of life)
Measured: At baseline, 3 months, and 6 months
Changes from baseline at 3 and 6 months in total serum estradiol concentration
The concentration of estradiol in serum in all forms, measured in pg/mL
Measured: At baseline, 3 months, and 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Sep 2025
- Study start1 Nov 2025 (estimated)
- Primary completion28 Feb 2027 (estimated)
- Study completion28 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Stress Urinary Incontinence (SUI)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 115 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hanoi Medical University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nguyen Quang Du, Hanoi Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07186985
- Sponsor's protocol ID
- HMUIRB1843
- Status last verified
- Sep 2025
- First submitted
- 9 Sep 2025
- Last updated
- 22 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effectiveness of Combined Pelvic Floor Muscle Training and Vaginal Oestrogen Therapy in Postmenopausal Women With Stress Urinary Incontinence
- ClinicalTrials.gov ID
- NCT07186985
- Acronym / sponsor ID
- HMUIRB1843
- Keywords
- stress urinary incontinence (SUI), postmenopausal women, Pelvic Floor Muscle Training, Vaginal Oestrogen, Pelvic floor rehabilitation
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 115 participants (estimated)
- Lead sponsor
- Hanoi Medical UniversityUniversity, hospital or other
- Study start
- 1 Nov 2025 (estimated)
- Primary completion
- 28 Feb 2027 (estimated)
- Study completion
- 28 Feb 2027 (estimated)
- First posted
- 22 Sep 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this clinical trial is to investigate whether the combination of pelvic floor muscle training (PFMT) and topical estrogen is more effective in treating stress urinary incontinence (SUI) in postmenopausal women compared to topical estrogen alone. The trial will also analyze factors related to the outcomes of the combined therapy. The key questions this trial aims to answer are:
- Does the combination of PFMT and topical estrogen improve symptoms of stress urinary incontinence in postmenopausal women better than topical estrogen alone?
- Which factors are associated with the effectiveness of the combined therapy?
Researchers will compare the group receiving the combined therapy (pelvic floor muscle training plus topical estrogen) with the group receiving topical estrogen alone to determine whether adding PFMT to estrogen therapy provides additional treatment benefits for SUI in postmenopausal women.
Participants will:
- Be randomly assigned to one of two groups:
Group 1: Undergo a pelvic floor muscle training (PFMT) program combined with topical estrogen therapy (e.g., vaginal cream/application,...).
Group 2: Receive topical estrogen therapy alone (e.g., vaginal cream/application,...).
- Follow the assigned intervention protocol for a specified duration.
- Attend regular clinic visits for clinical examinations, assessment of incontinence severity, and related measurements.
- Monitor and record their incontinence symptoms and the frequency of urine leakage during daily activities.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| combination of PFMT and vaginal estrogen. | Experimental | Combination Product: Combined Pelvic Floor Muscle Training and Vaginal Oestrogen TherapyPatients were treated with a combination of a pelvic floor rehabilitation program and 0.5 mg vaginal estrogen. |
| vaginal estrogen | Active comparator | Drug: Vaginal estrogenPatients were treated with 0.5 mg topical vaginal estrogen |
Who may qualify
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (4 listed)
- Patients diagnosed with stress urinary incontinence.
- Women who have been naturally postmenopausal for at least 1 year or are postmenopausal due to bilateral oophorectomy (surgical removal of both ovaries).
- Have had sexual intercourse to ensure feasibility of urogenital tract examination and assessment.
- Patients who consent to participate in the study and comply with the treatment protocol, including performing pelvic floor muscle training (PFMT) and completing topical vaginal estrogen therapy.
Key exclusion criteria (14 listed)
- Patients with concomitant neurological disorders, urinary tract infections, prior pelvic radiotherapy, or congenital malformations of the lower urinary tract.
- Genitourinary malformations or fistulas causing continuous urinary incontinence.
- Genitourinary cancers or tumors of the urinary tract.
- History of spinal cord injury or central nervous system injury affecting the centers that control urination.
- Patients previously treated for stress urinary incontinence (SUI) (surgery, medications, exercises).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Combined Pelvic Floor Muscle Training and Vaginal Oestrogen TherapyGroup 1: * Patients were instructed to identify and sense their pelvic floor muscles and to perform contraction-hold-relaxation exercises. * Exercises were performed at a frequency of 8 sets per session, 3 sessions per week, progressing from the supine position (month 1), to sitting (month 2), and to standing (month 3). Training was monitored by an electronic diary app. (Appendix) * Six individual 45-minute intervention sessions at the center using biofeedback, under the supervision of a physical therapy technician. (Appendix) * The training program consisted of two parts: resistance training and pre-contraction training (the Knack technique). (Appendix) * Patients were prescribed and instructed to use 0.5 mg vaginal estrogen for 6 months according to the following regimen: * First 4 weeks: insert one 0.5 mg tablet nightly at bedtime. * Next 20 weeks: insert one 0.5 mg tablet at bedtime twice weekly, with 2-3 days between doses | Combination product | combination of PFMT and vaginal estrogen. |
| Vaginal estrogenPatients were prescribed and instructed to use 0.5 mg vaginal estrogen for 6 months according to the following regimen: First 4 weeks: insert one 0.5 mg tablet nightly at bedtime. Next 20 weeks: insert one 0.5 mg tablet at bedtime twice weekly, with 2-3 days between doses. | Drug | vaginal estrogen |
Primary outcome
Changes from baseline at 3 and 6 months in One-hour Pad test
Time frame: At baseline, 3 months, and 6 months
One-hour pad test: A noninvasive method that measures the amount of urine leakage collected in an absorbent pad. Standardized by the International Continence Society (ICS), it quantifies leakage during everyday activities, measured in grams (g)
6 secondary outcomes
Changes from baseline at 3 and 6 months in Patient Global Impression of Improvement (PGI-I scale)
Time frame: At baseline, 3 months, and 6 months
Changes from baseline at 3 and 6 months in International Consultation on Incontinence Questionnaire-Urinary Incontinence-Short Form (ICIQ-UI-SF scale)
Time frame: At baseline, 3 months, and 6 months
Changes from baseline at 3 and 6 months in Oxford Scale
Time frame: At baseline, 3 months, and 6 months
Changes from baseline at 3 and 6 months in Pelvic floor ultrasound assessment
Time frame: At baseline, 3 months, and 6 months
Changes from baseline at 3 and 6 months in Lower Urinary Tract Symptoms Quality of Life (ICIQ-LUTSqol scale)
Time frame: At baseline, 3 months, and 6 months
Changes from baseline at 3 and 6 months in total serum estradiol concentration
Time frame: At baseline, 3 months, and 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Sep 2025.
Related trials for Stress Urinary Incontinence (SUI)
Not yet recruiting
Anterior Bridge-Preserving Versus Conventional Early Apical Release in Bipolar Enucleation of the Prostate
Benign Prostatic Hyperplasia, Benign Prostatic Obstruction
Active, not recruiting
A Study to Assess the Safety and Effectiveness of the UrOActive® Artificial Urinary sPHincter (AUS)
Stress Urinary Incontinence (SUI)
Recruiting
Comparing the Effect of Two Types of Pelvic Floor Muscle Stimulation Devices to Improve Symptoms of Urinary Incontinence in Women.
Urinary Incontinence, Mixed Urinary Incontinence
Recruiting
The Effects of Expiratory Muscle Strength Training in Women With Stress Urinary Incontinence
Stress Urinary Incontinence (SUI)
Recruiting
Motor Imagery-Assisted Pelvic Floor Muscle Training for Stress Urinary Incontinence in Postmenopausal Women
Stress Urinary Incontinence (SUI)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing Combined Pelvic Floor Muscle Training and Vaginal Oestrogen Therapy and Vaginal estrogen in people with Stress Urinary Incontinence (SUI) and Postmenopausal Women, run by Hanoi Medical University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 22 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Du Nguyen Quang (+84 337828793, nguyenquangdu.hmuh@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes from baseline at 3 and 6 months in One-hour Pad test (time frame: At baseline, 3 months, and 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2025; AzTrials last refreshed its copy on 8 Nov 2026.